Markers for ovarian cancer: regan isoenzyme and other glycoproteins
- PMID: 63996
Markers for ovarian cancer: regan isoenzyme and other glycoproteins
Abstract
Since embryonic genes are not generally active in normal adult subjects and because certain of these genes are activated in cancer leading to ectopic synthesis, it is the difference between the ectopic level and the normal adult concentrations of embryonic gene products which we seek in developing "markers" for ovarian cancer. The carcinoplacental alkaline phosphatases corresponding to the term gestational phenotypes correlate positively with ovarian cancer as does hCG. Other fetal and placental glycoproteins whose presence is noted in ovarian cancer include CEA, alpha-FP, and Björklund's antigen. Antigens of mucinous cystadenocarcinoma have not yet been examined for their possible fetal or placental origins. The degree of concordance of expression of Regan isoenzyme and hCG is variable. Profiles of glycoproteins would appear to offer an opportunity to inquire more deeply into the nature of ovarian cancer and from this inquiry, one can expect to develop a system of markers which can be of clinical use.
Similar articles
-
Tumor markers for ovarian cancer.Int Adv Surg Oncol. 1979;2:155-76. Int Adv Surg Oncol. 1979. PMID: 95453 Review.
-
Regan isoenzyme and human chorionic gonadotropin in ovarian cancer.Natl Cancer Inst Monogr. 1975 Oct;42:63-73. Natl Cancer Inst Monogr. 1975. PMID: 1234637
-
Tumour markers in ovarian cancer.Clin Obstet Gynaecol. 1983 Aug;10(2):197-212. Clin Obstet Gynaecol. 1983. PMID: 6193919 No abstract available.
-
Elevation of histaminase and its concurrence with Regan isoenzyme in ovarian cancer.Cancer Res. 1975 Oct;35(10):2762-5. Cancer Res. 1975. PMID: 808268
-
Immunology and biochemistry of the Regan isoenzyme.Prostate. 1980;1(4):399-410. doi: 10.1002/pros.2990010403. Prostate. 1980. PMID: 7024957 Review.
Cited by
-
History, molecular features, and clinical importance of conventional serum biomarkers in lung cancer.Surg Today. 2017 Sep;47(9):1037-1059. doi: 10.1007/s00595-017-1477-y. Epub 2017 Feb 22. Surg Today. 2017. PMID: 28229299 Review.
-
Tumorigenic and Immunogenic Properties of Induced Pluripotent Stem Cells: a Promising Cancer Vaccine.Stem Cell Rev Rep. 2020 Dec;16(6):1049-1061. doi: 10.1007/s12015-020-10042-5. Epub 2020 Sep 16. Stem Cell Rev Rep. 2020. PMID: 32939647 Free PMC article. Review.
-
Induced Pluripotent Stem Cell-Based Cancer Vaccines.Front Immunol. 2019 Jul 8;10:1510. doi: 10.3389/fimmu.2019.01510. eCollection 2019. Front Immunol. 2019. PMID: 31338094 Free PMC article. Review.
-
Activity of antibodies recovered from immune complexes of ovarian cancer patients.Cancer Immunol Immunother. 1984;17(3):180-9. doi: 10.1007/BF00205483. Cancer Immunol Immunother. 1984. PMID: 6383602 Free PMC article.